M. Petri

Publications958
h-index133
Citations66,525
Highly Influential Citations2,299
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • D. Isenberg
  • 1,672 Publications • 71,747 Citations
  • D. Gladman
  • 1,301 Publications • 77,306 Citations
  • R. Ramsey‐Goldman
  • 439 Publications • 25,240 Citations
  • M. Urowitz
  • 512 Publications • 32,781 Citations
  • Publications
  • Influence
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.
OBJECTIVE The Systemic Lupus International Collaborating Clinics (SLICC) group revised and validated the American College of Rheumatology (ACR) systemic lupus erythematosus (SLE) classification…
View on PubMed
The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.
TLDR
This damage index for SLE records damage occurring in patients with SLE regardless of its cause and was demonstrated to have content, face, criterion, and discriminant validity.
View on PubMed
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
View on Elsevier
Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX.
TLDR
The authors identified and then confirmed through replication two new genetic loci for SLE: a promoter-region allele associated with reduced expression of BLK and increased expression of C8orf13 and variants in the ITGAM-ITGAX region.
View on PubMed
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
TLDR
Belimumab plus standard therapy significantly improved SRI response rate, reduced SLE disease activity and severe flares, and was generally well tolerated in SLE.
View on PubMed
A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus
TLDR
The results expand the number of confirmed and candidate SLE susceptibility loci and implicate several key immunologic pathways in SLE pathogenesis.
View on Nature
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.
TLDR
In this 24-week randomized, open-label, noninferiority trial, mycophenolate mofetil was more effective than intravenous cyclophosphamide in inducing remission of lupus nephritis and had a more favorable safety profile.
View on PubMed
Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE.
TLDR
Genotyped 525 independent North American white individuals with systemic lupus erythematosus and compared the results with data generated from 1,961 white control individuals provide compelling evidence that PTPN22 plays a fundamental role in regulating the immune system and the development of autoimmunity.
View on PubMed
Combined Oral Contraceptives in Women With Systemic Lupus Erythematosus
TLDR
This study indicates that oral contraceptives do not increase the risk of flare among women with systemic lupus erythematosus whose disease is stable and is within the prespecified 9 percent margin for noninferiority.
View on Wolters Kluwer
Distinct Effector B Cells Induced by Unregulated Toll‐like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus
View on Wolters Kluwer
...
...